Key ASCO Presentations on GI Cancer

Asco Logo snipped

A number of AGITG members attended this year’s American Society of Clinical Oncology (ASCO) meeting in Chicago (2-6 June).

Following ASCO NEJM Journal Watch Oncology and Hematology have published an article which provides reviews by Associate Editor David H. Ilson, MD, PhD, of key presentations on new Gastro-Intestinal cancer treatments.

The NEJM Journal article – which you can read in full HERE – provides a summary on each of the below:

Duration of Colon Cancer Therapy: 3 or 6 Months?

Vitamin D of Modest Benefit in Metastatic Colon Cancer

Vemurafenib Improves Survival in Metastatic Colorectal Cancer

Radiotherapy Ineffective for Liver Metastases from CRC

Prognostic Factors in Metastatic CRC

Perioperative Chemotherapy for Gastric Cancer: A New Standard

Pembrolizumab Active in Advanced Gastric Cancer

Capecitabine Bests Observation for Biliary Tract Cancer

No Improvement with SIRT for Locally Advanced HCC

Lenvatinib Effective for Unresectable HCC

 

Full abstracts on each of the above can also be found on the ASCO site HERE